Metagenomi, Inc.

As of August 25, 2025, Metagenomi, Inc. shows a mildly bearish trend despite recent outperformance against the S&P 500, with returns of 13.23% and 11.46% over the past week and month, but significant year-to-date and one-year losses of -40.72% and -19.55%.

As of May 1, 2025, Metagenomi, Inc. has a mildly bearish outlook due to bearish daily moving averages, despite some mildly bullish signals from the weekly MACD and KST.

Metagenomi, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $4 million and a net loss of $25 million as of March 2025, with a market cap of $54.58 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -32.34%.

As of Jun 18, Metagenomi, Inc. has a market capitalization of 54.58 million and reported net sales of 45.26 million with a net profit of -77.95 million over the latest four quarters. Shareholder's funds are 234.86 million, and total assets amount to 324.60 million.